Kristin Yarema - Jan 2, 2024 Form 4 Insider Report for Poseida Therapeutics, Inc. (PSTX)

Role: President and CEO, Director
Signature: /s/ Harry J.Leonhardt, Attorney-in-Fact
Stock symbol: PSTX
Transactions as of: Jan 2, 2024
Transactions value $: $0
Form type: 4
Date filed: 1/4/2024, 04:03 PM
Previous filing: Apr 12, 2023

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	PSTX	Common Stock	Award	$0	+250K	+70.06%	$0.00	607K	Jan 2, 2024	Direct	F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	PSTX	Stock Option (Right to buy)	Award	$0	+345K		$0.00	345K	Jan 2, 2024	Common Stock	345K	$3.38	Direct	F2

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	Represents shares issuable upon the vesting of restricted stock units granted pursuant to the Issuer's Equity Incentive Plan. The RSUs are scheduled to vest in four equal annual installments beginning from the first anniversary of January 1, 2024.
F2	12.5% of the shares subject to the stock option will vest and become exercisable on the six-month anniversary of January 1, 2024, and the remaining shares will vest in 42 equal monthly installments thereafter.